The effect of recombinant human osteogenic protein-1 on allograft incorporation.
We used a canine intercalary bone defect model to determine the effects of recombinant human osteogenic protein 1 (rhOP-1) on allograft incorporation. The allograft was treated with an implant made up of rhOP-1 and type I collagen or with type I collagen alone. Radiographic analysis showed an increased volume of periosteal callus in both test groups compared with the control group at weeks 4, 6, 8 and 10. Mechanical testing after 12 weeks revealed increased maximal torque and stiffness in the rhOP-1 treated groups compared with the control group. These results indicate a benefit from the use of an rhOP-1 implant in the healing of bone allografts. The effect was independent of the position of the implant. There may be a beneficial clinical application for this treatment.
Lietman
S A
SA
Department of Orthopaedic Surgery, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA. lietmas@ccf.org
Inoue
N
N
Rafiee
B
B
Deitz
L W
LW
Chao
E Y S
EY
D000818:Animals; D001696:Biomechanical Phenomena; D016025:Bone Transplantation / Q000379:methods*; D024042:Collagen Type I / Q000494:pharmacology; D004195:Disease Models, Animal; D004285:Dogs; D016503:Drug Delivery Systems; D016348:Osseointegration / Q000187:drug effects*; D011506:Proteins / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D016474:Weight-Bearing
D024042:Collagen Type I; D011506:Proteins; D011994:Recombinant Proteins